Detection of high levels of mutations involved in anti-malarial drug resistance in Plasmodium falciparum and Plasmodium vivax at a rural hospital in southern Ethiopia

Malaria Journal

Volumn 10, Issue , 2011, Pages

  Mula, Patricia ^a   Fernández Martínez, Amalia ^a   De Lucio, Aida ^a   Ramos, Jose ^b,c   Reyes, Francisco ^b   González, Vicenta ^a   Benito, Agustín ^a   Berzosa, Pedro ^a  

^a Red de Investigación de Centros de Enfermedades Tropicales RICET Madrid   (Spain)

^b Gambo General Rural Hospital   (Ethiopia)

^c HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROQUINE; ANTIMALARIAL AGENT; CARRIER PROTEIN; DIHYDROFOLATE REDUCTASE; DIHYDROPTEROATE SYNTHASE; MDR1 PROTEIN, PLASMODIUM FALCIPARUM; MULTIDRUG RESISTANCE PROTEIN; PFCRT PROTEIN, PLASMODIUM FALCIPARUM; PROTOZOAL DNA; PROTOZOAL PROTEIN;

ADOLESCENT; ADULT; AGED; ANTIMALARIAL DRUG RESISTANCE; ARTICLE; CHILD; ETHIOPIA; GENE MUTATION; GENETIC POLYMORPHISM; HOSPITAL; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; NONHUMAN; PLASMODIUM FALCIPARUM; PLASMODIUM OVALE; PLASMODIUM OVALE MALARIA; PLASMODIUM VIVAX; PLASMODIUM VIVAX MALARIA; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PREVALENCE; RURAL AREA; SCHOOL CHILD; DRUG EFFECT; DRUG RESISTANCE; GENETICS; MIDDLE AGED; MISSENSE MUTATION; PARASITOLOGY;

ADOLESCENT; ADULT; AGED; ANTIMALARIALS; CHILD; CHILD, PRESCHOOL; DIHYDROPTEROATE SYNTHASE; DNA, PROTOZOAN; DRUG RESISTANCE; ETHIOPIA; HOSPITALS, RURAL; HUMANS; INFANT; MALARIA, FALCIPARUM; MALARIA, VIVAX; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; MUTATION, MISSENSE; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PROTOZOAN PROTEINS; TETRAHYDROFOLATE DEHYDROGENASE; YOUNG ADULT;

EID: 79960889534     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-10-214     Document Type: Article

References (46)

1. World Malaria Report 2009. WHO, Geneva: World Health Organization 2009
2. Climate change and human health: present and future risks. McMichael AJ, Woodruff RE, Hales S, Lancet 2006 367 859 869 10.1016/S0140-6736(06)68079-3 16530580 (Pubitemid 43363373)
3. World Malaria Report 2008. WHO, Geneva: World Health Organization 2008
4. Guideline for malaria epidemic prevention and control in Ethiopia. Federal Democratic Republic of Ethiopia MoH, Addis Ababa, Ethiopia 2004
5. National Five Year Strategic Plan for Malaria Prevention and Control in Ethiopia. Federal Democratic Republic of Ethiopia MoH, Addis Ababa, Ethiopia 2006
6. Spatial and temporal variations of malaria epidemic risk in Ethiopia: factors involved and implications. Abeku TA, van Oortmarssen GJ, Borsboom G, De Vlas SJ, Habbema JD, Acta Trop 2003 87 331 340 10.1016/S0001-706X(03)00123-2 12875926 (Pubitemid 37271999)
7. The ecology of health and disease in Ethiopia. Malaria. Tulu AN, Westview Press, Zein Ahmed Z, Kloos H, 1993 341 352
8. The 2003 malaria situation in Ethiopia. Proceedings of the Panel Discussion on the 2003 Malaria Epidemics in Ethiopia. Jima D, Addis Ababa, Ethiopia 2004
9. Self-treatment of malaria in rural communities, Butajira, southern Ethiopia. Deressa W, Ali A, Enqusellassie F, Bull World Health Organ 2003 81 261 268 12764492 (Pubitemid 36542142)
10. Association between climate variability and malaria epidemics in the East African highlands. Zhou G, Minakawa N, Githeko AK, Yan G, Proc Natl Acad Sci USA 2004 101 2375 2380 10.1073/pnas.0308714100 14983017 (Pubitemid 38269319)
11. Analysis of pfcrt, pfmdr1, dhfr, and dhps mutations and drug sensitivities in Plasmodium falciparum isolates from patients in Vietnam before and after treatment with artemisinin. Ngo T, Duraisingh M, Reed M, Hipgrave D, Biggs B, Cowman AF, Am J Trop Med Hyg 2003 68 350 356 12685644 (Pubitemid 38240527)
12. Molecular markers for drug resistance in malaria: use in treatment, diagnosis and epidemiology. Wernsdorfer WH, Noedl H, Curr Opin Infect Dis 2003 16 553 558 10.1097/00001432-200312000-00007 14624105
13. Primaquine-tolerant vivax malaria in Thailand. Looareesuwan S, Buchachart K, Wilairatana P, Chalermrut K, Rattanapong Y, Amradee S, Siripiphat S, Chullawichit S, Thimasan K, Ittiverakul M, Triampon A, Walsh DS, Ann Trop Med Parasitol 1997 91 939 943 9579214 (Pubitemid 28019796)
14. Vivax malaria resistant to treatment and prophylaxis with chloroquine. Murphy GS, Basri H, Purnomo, Andersen EM, Bangs MJ, Mount DL, Gorden J, Lal AA, Purwokusumo AR, Harjosuwarno S, Lancet 1993 341 96 100 10.1016/0140-6736(93) 92568-E 8093414 (Pubitemid 23028126)
15. Similar trends of pyrimethamine resistance-associated mutations in Plasmodium vivax and P. falciparum. Alam MT, Bora H, Bharti PK, Saifi MA, Das MK, Dev V, Kumar A, Singh N, Dash AP, Das B, Wajihullah, Sharma YD, Antimicrob Agents Chemother 2007 51 857 863 10.1128/AAC.01200-06 17194833 (Pubitemid 46355267)
16. Dihydrofolate reductase mutations in Plasmodium vivax from Indonesia and therapeutic response to sulfadoxine plus pyrimethamine. Hastings MD, Porter KM, Maguire JD, Susanti I, Kania W, Bangs MJ, Sibley CH, Baird JK, J Infect Dis 2004 189 744 750 10.1086/381397 14767830 (Pubitemid 38270930)
17. Association of genetic mutations in Plasmodium vivax dhfr with resistance to sulfadoxine-pyrimethamine: geographical and clinical correlates. Imwong M, Pukrittakayamee S, Looareesuwan S, Pasvol G, Poirreiz J, White NJ, Snounou G, Antimicrob Agents Chemother 2001 45 3122 3127 10.1128/AAC.45.11.3122-3127.2001 11600366 (Pubitemid 32988838)
18. Novel point mutations in the dihydrofolate reductase gene of Plasmodium vivax: evidence for sequential selection by drug pressure. Imwong M, Pukrittayakamee S, Renia L, Letourneur F, Charlieu JP, Leartsakulpanich U, Looareesuwan S, White NJ, Snounou G, Antimicrob Agents Chemother 2003 47 1514 1521 10.1128/AAC.47.5.1514-1521.2003 12709316 (Pubitemid 36548531)
19. Sequence variations in the Plasmodium vivax dihydrofolate reductase-thymidylate synthase gene and their relationship with pyrimethamine resistance. de Pecoulas PE, Tahar R, Ouatas T, Mazabraud A, Basco LK, Mol Biochem Parasitol 1998 92 265 273 10.1016/S0166-6851(97)00247-8 9657331 (Pubitemid 28248099)
20. Therapeutic responses to different antimalarial drugs in vivax malaria. Pukrittayakamee S, Chantra A, Simpson JA, Vanijanonta S, Clemens R, Looareesuwan S, White NJ, Antimicrob Agents Chemother 2000 44 1680 1685 10.1128/AAC.44.6. 1680-1685.2000 10817728 (Pubitemid 30340814)
21. Sulfadoxine resistance in Plasmodium vivax is associated with a specific amino acid in dihydropteroate synthase at the putative sulfadoxine-binding site. Korsinczky M, Fischer K, Chen N, Baker J, Rieckmann K, Cheng Q, Antimicrob Agents Chemother 2004 48 2214 2222 10.1128/AAC.48.6.2214-2222.2004 15155224 (Pubitemid 38691621)
22. Safety and efficacy of artemether-lumefantrine in the treatment of uncomplicated falciparum malaria in Ethiopia. Jima D, Tesfaye G, Medhin A, Kebede A, Argaw D, Babaniyi O, East Afr Med J 2005 82 387 390 16261913 (Pubitemid 41539862)
23. Efficacy and safety of intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in African infants: a pooled analysis of six randomised, placebo-controlled trials. Aponte JJ, Schellenberg D, Egan A, Breckenridge A, Carneiro I, Critchley J, Danquah I, Dodoo A, Kobbe R, Lell B, May J, Premji Z, Sanz S, Sevene E, Soulaymani-Becheikh R, Winstanley P, Adjei S, Anemana S, Chandramohan D, Issifou S, Mockenhaupt F, Owusu-Agyei S, Greenwood B, Grobusch MP, Kremsner PG, Macete E, Mshinda H, Newman RD, Slutsker L, Tanner M, Alonso P, Menendez C, Lancet 2009 374 1533 1542 10.1016/S0140-6736(09)61258-7 19765816
24. Epidemiology of drug-resistant malaria. Wongsrichanalai C, Pickard AL, Wernsdorfer WH, Meshnick SR, Lancet Infect Dis 2002 2 209 218 10.1016/S1473-3099(02)00239-6 11937421 (Pubitemid 34464751)
25. Genetics of drug-resistant Plasmodium falciparum malaria in the Venezuelan state of Bolivar. Contreras CE, Cortese JF, Caraballo A, Plowe CV, Am J Trop Med Hyg 2002 67 400 405 12452494 (Pubitemid 35303864)
26. Mutations in the pfmdr1, dhfr and dhps genes of Plasmodium falciparum are associated with in-vivo drug resistance in West Papua, Indonesia. Nagesha HS, Din S, Casey GJ, Susanti AI, Fryauff DJ, Reeder JC, Cowman AF, Trans R Soc Trop Med Hyg 2001 95 43 49 10.1016/S0035-9203(01)90329-3 11280065 (Pubitemid 34202224)
27. Towards an understanding of the mechanism of pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: genotyping of dihydrofolate reductase and dihydropteroate synthase of Kenyan parasites. Nzila AM, Mberu EK, Sulo J, Dayo H, Winstanley PA, Sibley CH, Watkins WM, Antimicrob Agents Chemother 2000 44 991 996 10.1128/AAC.44.4.991-996.2000 10722502 (Pubitemid 30165281)
28. Short communication: point mutations in the dihydrofolate reductase and dihydropteroate synthase genes of Plasmodium falciparum isolates from Colombia. Schmider N, Peyerl-Hoffmann G, Restrepo M, Jelinek T, Trop Med Int Health 2003 8 129 132 10.1046/j.1365-3156.2003.01005.x 12581437 (Pubitemid 36269363)
29. Pyrimethamine resistance in Plasmodium vivax malaria. Young MD, Burgess RW, Bull World Health Organ 1959 20 27 36 13638787
30. Molecular characterization of antifolates resistance-associated genes, (dhfr and dhps) in Plasmodium vivax isolates from the Middle East. Zakeri S, Motmaen SR, Afsharpad M, Djadid ND, Malar J 2009 8 20 10.1186/1475-2875-8-20 19175936
31. Amino acid mutations in Plasmodium vivax DHFR and DHPS from several geographical regions and susceptibility to antifolate drugs. Auliff A, Wilson DW, Russell B, Gao Q, Chen N, Anh lN, Maguire J, Bell D, O'Neil MT, Cheng Q, Am J Trop Med Hyg 2006 75 617 621 17038682 (Pubitemid 46941264)
32. Sensitivity to antifolates and genetic analysis of Plasmodium vivax isolates from Thailand. Rungsihirunrat K, Na-Bangchang K, Hawkins VN, Mungthin M, Sibley CH, Am J Trop Med Hyg 2007 76 1057 1065 17556611 (Pubitemid 351837866)
33. Prevalence of antimalarial drug resistance mutations in Plasmodium vivax and P. falciparum from a malaria-endemic area of Pakistan. Khatoon L, Baliraine FN, Bonizzoni M, Malik SA, Yan G, Am J Trop Med Hyg 2009 81 525 528 19706926
34. Plasmodium vivax dihydrofolate reductase point mutations from the Indian subcontinent. Kaur S, Prajapati SK, Kalyanaraman K, Mohmmed A, Joshi H, Chauhan VS, Acta Trop 2006 97 174 180 10.1016/j.actatropica.2005.10.003 16310156 (Pubitemid 43087751)
35. Antifolates can have a role in the treatment of Plasmodium vivax. Hawkins VN, Joshi H, Rungsihirunrat K, Na-Bangchang K, Sibley CH, Trends Parasitol 2007 23 213 222 10.1016/j.pt.2007.03.002 17368986 (Pubitemid 46621225)
36. Therapeutic efficacies of artesunate-sulfadoxine-pyrimethamine and chloroquine-sulfadoxine-pyrimethamine in vivax malaria pilot studies: relationship to Plasmodium vivax dhfr mutations. Tjitra E, Baker J, Suprianto S, Cheng Q, Anstey NM, Antimicrob Agents Chemother 2002 46 3947 3953 10.1128/AAC.46.12.3947-3953.2002 12435700 (Pubitemid 35403273)
37. Molecular surveillance of Plasmodium vivax dhfr and dhps mutations in isolates from Afghanistan. Zakeri S, Afsharpad M, Ghasemi F, Raeisi A, Safi N, Butt W, Atta H, Djadid ND, Malar J 2010 9 75 10.1186/1475-2875-9-75 20226087
38. Semi-nested, multiplex polymerase chain reaction for detection of human malaria parasites and evidence of Plasmodium vivax infection in Equatorial Guinea. Rubio JM, Benito A, Roche J, Berzosa PJ, Garcia ML, Mico M, Edu M, Alvar J, Am J Trop Med Hyg 1999 60 183 187 10072133 (Pubitemid 29107099)
39. -2002 PCR-ASRA Protocols for Plasmodium falciparum Drug-Resistance Mutation Analysis. http://medschool.umaryland.edu/CVD/2002-pcr-asra.asp
40. pfmdr1 mutations in imported African Plasmodium falciparum isolates. Dippmann AK, Bienzle U, Harms G, Mockenhaupt FP, Trans R Soc Trop Med Hyg 2008 102 1148 1150 10.1016/j.trstmh.2008.04.001 18513774
41. Two-sided confidence intervals for the single proportion: comparison of seven methods. Newcombe RG, Stat Med 1998 17 857 872 10.1002/(SICI)1097- 0258(19980430)17:8<857::AID-SIM777>3.0.CO;2-E 9595616 (Pubitemid 28185165)
42. An in-vivo study of falciparum malaria sensitivity to Chloroquine in unstable malaria endemic area of central Ethiopia. Kebede F, Taffa N, Tedla T, Ethiop Med J 1999 37 97 109 11957310
43. High prevalence of drug-resistance mutations in Plasmodium falciparum and Plasmodium vivax in southern Ethiopia. Schunk M, Kumma WP, Miranda IB, Osman ME, Roewer S, Alano A, Loscher T, Bienzle U, Mockenhaupt FP, Malar J 2006 5 54 10.1186/1475-2875-5-54 16817953 (Pubitemid 44141486)
44. Prevalence of malaria from peripheral blood smears examination: a 1-year retrospective study from the Serbo Health Center, Kersa Woreda, Ethiopia. Karunamoorthi K, Bekele M, J Infect Public Health 2009 2 171 176 10.1016/j.jiph.2009.08.005 20701879
45. A molecular marker for chloroquine-resistant falciparum malaria. Djimde A, Doumbo OK, Cortese JF, Kayentao K, Doumbo S, Diourte Y, Dicko A, Su XZ, Nomura T, Fidock DA, Wellems TE, Plowe CV, Coulibaly D, N Engl J Med 2001 344 257 263 10.1056/NEJM200101253440403 11172152 (Pubitemid 32108530)
46. Chloroquine-treatment failure in northern Ghana: roles of pfcrt T76 and pfmdr1 Y86. Mockenhaupt FP, Ehrhardt S, Eggelte TA, Agana-Nsiire P, Stollberg K, Mathieu A, Markert M, Otchwemah RN, Bienzle U, Ann Trop Med Parasitol 2005 99 723 732 10.1179/136485905X75395 16297285 (Pubitemid 41695613)